Vol. 2 No. 11 (2022)
Reimbursement Recommendations

Pegvaliase (Palynziq)

Published November 25, 2022

Key Messages

  • CADTH recommends that Palynziq should be reimbursed by public drug plans for the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) on existing management if certain conditions are met.
  • Palynziq should only be covered to treat patients with PKU aged 16 years and older.
  • Palynziq should only be reimbursed for patients who demonstrate and maintain a response to treatment (blood phenylalanine levels less than 600 µmol/L), if the drug is prescribed by a clinician with expertise in treating genetic and metabolic disorders, and if the cost of Palynziq is reduced.